Wave of FDA Warning Letters to Injectable Compounders in Q1 2014 Follows 2013 Inspection Blitz and Legislative Empowerment; Reci The FDA has issued warning letters to multiple companies marketing compounded Retatrutide, an investigational drug from Eli Lilly still in Phase II trials. While early studies have shown promising weight loss results, Retatrutide Is Your Peptide Store Website FDA Aligned? onPoint Studio Web Design and Development Services Compounded "semaglutide" is not FDA approved semaglutide.com FDA to weigh easing limits on unproven peptides favored by RFK Jr. and MAHA supporters PBS News